Biotech | October 13, 2021
Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Industry leaders to increase patient access to clinical research and scale remote enrollment of participants for trial sponsors to promote increased health equity
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
Subscribe To Our Newsletter & Stay Updated
